玻璃体内注射血管内皮生长因子抑制剂：实用方法
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.
作者信息
Petri Anne-Sofie, Boysen Kirstine, Cehofski Lasse J, van Dijk Elon H C, Dysli Chantal, Fuchs Josefine, Mastropasqua Rodolfo, Subhi Yousif
机构信息
Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
出版信息
Ophthalmol Ther. 2020 Mar;9(1):191-203. doi: 10.1007/s40123-020-00230-4. Epub 2020 Feb 7.
Abstract
Intravitreal injections with vascular endothelial growth factor inhibitors constitute the most prevalent ophthalmic procedure in developed countries. Historically, there has been steady growth in the number of treatments performed of this kind, and projection studies estimate further growth in such treatments in the future. We provide a practical approach to intravitreal injections and discuss important aspects relating to the setting, the patient, the procedure, and the information given to the patient.
摘要
玻璃体内注射血管内皮生长因子抑制剂是发达国家最常见的眼科手术。从历史上看，这类治疗的实施数量一直在稳步增长，预测研究估计未来此类治疗还会进一步增加。我们提供了一种玻璃体内注射的实用方法，并讨论了与治疗环境、患者、手术过程以及向患者提供的信息相关的重要方面。
相似文献
1
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.
Ophthalmol Ther. 2020 Mar;9(1):191-203. doi: 10.1007/s40123-020-00230-4. Epub 2020 Feb 7.
2
Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.
BMC Nephrol. 2019 Dec 26;20(1):478. doi: 10.1186/s12882-019-1650-1.
3
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
4
High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Ophthalmology. 2016 Jun;123(6):1257-62. doi: 10.1016/j.ophtha.2016.02.015. Epub 2016 Mar 12.
5
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Am J Ophthalmol. 2018 Oct;194:1-6. doi: 10.1016/j.ajo.2018.06.022. Epub 2018 Jul 6.
6
Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
J Med Case Rep. 2021 Jul 27;15(1):403. doi: 10.1186/s13256-021-02983-3.
7
Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.
8
Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Ophthalmol Retina. 2021 Apr;5(4):357-364. doi: 10.1016/j.oret.2020.08.005. Epub 2020 Aug 17.
9
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Steroid for Treatment-Naive Diabetic Macular Edema in a Real-Life Setting.
J Ocul Pharmacol Ther. 2020 Sep;36(7):555-562. doi: 10.1089/jop.2020.0012. Epub 2020 May 12.
10
Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Clinical Practice of Single Center: Three-Year Outcomes.
Ophthalmic Res. 2021;64(3):483-493. doi: 10.1159/000512300. Epub 2020 Oct 14.
引用本文的文献
1
Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.
Ophthalmol Ther. 2025 Aug 9. doi: 10.1007/s40123-025-01220-0.
2
Treatment Interval Progression and Adherence to Observe-and-Plan Regimen for Neovascular Age-Related Macular Degeneration Treated with Aflibercept 2 mg.
Ophthalmol Ther. 2025 Mar;14(3):585-597. doi: 10.1007/s40123-025-01095-1. Epub 2025 Feb 3.
3
Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases.
Am J Ophthalmol. 2024 Dec 21. doi: 10.1016/j.ajo.2024.12.010.
4
Downregulation of rhodopsin is an effective therapeutic strategy in ameliorating peripherin-2-associated inherited retinal disorders.
Nat Commun. 2024 Jun 4;15(1):4756. doi: 10.1038/s41467-024-48846-5.
5
Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2153-2162. doi: 10.1007/s00417-024-06421-0. Epub 2024 Feb 28.
6
Effect of Needle Gauge Size on Pain During Intravitreal Anti-VEGF Injection: A Systematic Review and Network Meta-Analysis.
Ophthalmol Ther. 2024 Mar;13(3):801-817. doi: 10.1007/s40123-023-00879-7. Epub 2024 Jan 24.
7
Therapeutic effects of herbal medicines in different types of retinopathies: A systematic review.
Avicenna J Phytomed. 2023 Mar-Apr;13(2):118-142. doi: 10.22038/AJP.2022.62423.2977.
8
Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses.
J Pers Med. 2023 Mar 18;13(3):546. doi: 10.3390/jpm13030546.
9
Macular Edema in Central Retinal Vein Occlusion Correlates With Aqueous Fibrinogen Alpha Chain.
Invest Ophthalmol Vis Sci. 2023 Feb 1;64(2):23. doi: 10.1167/iovs.64.2.23.
10
Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion.
Molecules. 2022 May 24;27(11):3360. doi: 10.3390/molecules27113360.
本文引用的文献
1
Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.
JAMA Ophthalmol. 2020 Jan 1;138(1):50-57. doi: 10.1001/jamaophthalmol.2019.4636.
2
Low health literacy levels in patients with chronic retinal disease.
BMC Ophthalmol. 2019 Aug 8;19(1):174. doi: 10.1186/s12886-019-1191-1.
3
Indoor hospital air and the impact of ventilation on bioaerosols: a systematic review.
J Hosp Infect. 2019 Oct;103(2):175-184. doi: 10.1016/j.jhin.2019.06.016. Epub 2019 Jul 4.
4
Task shifting of intraocular injections from physicians to nurses: a randomized single-masked noninferiority study.
Acta Ophthalmol. 2020 Mar;98(2):139-144. doi: 10.1111/aos.14184. Epub 2019 Jul 3.
5
[Patient's Knowledge after Informed Consent for Intravitreal Injections].
Klin Monbl Augenheilkd. 2021 Jun;238(6):721-726. doi: 10.1055/a-0886-6507. Epub 2019 Jun 19.
6
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis.
Ophthalmol Retina. 2018 Nov;2(11):1087-1096. doi: 10.1016/j.oret.2018.04.018. Epub 2018 Jun 11.
7
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
8
Irrigating the eye after intravitreal injection reduces epithelial damage but not patient discomfort.
Acta Ophthalmol. 2019 Jun;97(4):e670-e671. doi: 10.1111/aos.14014. Epub 2019 Jan 8.
9
Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.
J Ophthalmol. 2018 Jul 24;2018:8567912. doi: 10.1155/2018/8567912. eCollection 2018.
10
Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
JAMA Ophthalmol. 2018 May 1;136(5):557-566. doi: 10.1001/jamaophthalmol.2018.0002.
Zotero 插件